Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration

Wei, Yanli; Hong-xia, Liao; Ye, Jian

doi:10.1097/md.0000000000010422

Cited by 10 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…168,266 ◆ Bevacizumab injection  Reported safety data are limited by relatively short and variable follow-up periods and by differences in reporting criteria. 267,268  Reported ocular adverse events include bacterial endophthalmitis per injection (0.16%), tractional retinal detachments (0.16%), uveitis (0.09%), rhegmatogenous retinal detachment (0.02%), and vitreous hemorrhage (0.16%). 240,269 The CATT study had limited statistical power to identify any differences in treatmentrelated adverse events between bevacizumab and ranibizumab.…”

Section: Difficulties In Dark Adaptationmentioning

confidence: 99%

Age-Related Macular Degeneration Preferred Practice Pattern®

et al. 2020

View full text Add to dashboard Cite

Section: Difficulties In Dark Adaptationmentioning

confidence: 99%

Age-Related Macular Degeneration Preferred Practice Pattern®

et al. 2020

View full text Add to dashboard Cite

“…Of 2144 records identified in the management search, 10 publications were included ( Figure 1 B). [29][30][31][32][33][34][35][36][37][38] Two publications were from the United Kingdom, 32 , 33 2 from other European countries, 36 , 37 and 6 from unspecified countries or regions. 29-31 , 34 , 35 , 38 One AMD treatment guideline, 1 guidance on an implant system, 6 literature reviews that provided an overview of AMD/dry AMD management, and 2 dry AMD abstracts from the 2018 EURETINA conference were included.…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review

Schultz

Bhardwaj

Barclay

et al. 2021

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: Age-related macular degeneration (AMD) is a leading cause of blindness, particularly in higherincome countries. Although dry AMD accounts for 85% to 90% of AMD cases, a comprehensive understanding of the global dry AMD burden is needed.Methods: A targeted literature review was conducted in PubMed, MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (1995Reviews ( -2019 to identify data on the epidemiology, management, and humanistic and economic burden of dry AMD in adults. A landscape analysis of patientreported outcome (PRO) instruments in AMD was also conducted via searches in PubMed (1995PubMed ( -2019, ClinicalTrials.gov, PROQOLID, PROLABELS, and health technology assessment reports (2008)(2009)(2010)(2011)(2012)(2013)(2014)(2015)(2016)(2017)(2018).Findings: Thirty-seven of 4205 identified publications were included in the review. Dry AMD prevalence was 0.44% globally, varied across ethnic groups, and increased with age. Patients with dry AMD had higher risks of all-cause mortality (hazard ratio [HR] = 1.46; 95% CI, 0.99-2.16) and tobacco-related (HR = 2.86; 95% CI, 1.15-7.09) or cancer deaths (HR = 3.37; 95% CI, 1.56-7.29; P = 0.002) than those without dry AMD. Smoking, increasing age or cholesterol levels, and obesity are key risk factors for developing dry AMD. No treatment guidelines were identified for dry AMD specifically; management focuses on risk factor reduction and use of dietary supplements. In the United States and Italy, direct medical costs and health care resource utilization were lower in patients with dry versus wet AMD. Patients with dry AMD, particularly advanced disease, experienced significant visual function impairment. Dry AMD symptoms included reduced central vision, decreased ability to see at night, increased visual blurriness, distortion of straight lines and text, and faded color vision. Most PRO instruments used in AMD evaluations covered few, if any, of the identified symptoms reported by patients with dry AMD. Although the Quality of Life and Vision Function Questionnaire, 25-item National Eye Institute Vision Function Questionnaire, Low Vision Quality of Life, Impact of Vision Impairment-Very Low Vision, and Functional Reading Independence Index had strong content validity and psychometric properties in patients with dry AMD, they retained limited coverage of salient concepts.Implications: Despite dry AMD accounting for most AMD cases, there are substantial gaps in the published literature, particularly the humanistic and economic burden of disease and the lack of differentiation among dry, wet, or unspecified dry AMD. The significant burden of illness alludes to a high unmet need for tolerable and effective treatment options, as well as PRO instruments with more coverage of dry AMD symptoms and salient concepts. ( Clin Ther.

show abstract

“…There are still no treatments that slow progression of dry AMD. Ongoing clinical trials continue to pursue new drugs for the purpose of preventing and/or treating dry AMD, although some intitially promising complement pathway inhibitors (such as lampalizumab) have failed to achieve expected outcomes in clinical trials, a number of compelling prospects remain [13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,35,36,37,38,39,40,41,42]. Currently, APL-2, which binds the C3 protein blocking all three pathways of complement activation, may be the most promising molecule [26,27,28,40,41].…”

Section: Discussionmentioning

confidence: 99%

“…The inhibition of C5 in the complement cascade prevents the formation of key terminal fragments (C5a and C5b-9). C5b-9 is involved in the formation of the MAC, which causes cellular death through the disruption of the cell membrane [22,23,24]. A phase 1 trial for dry AMD (NCT00950638), started in 2009, was completed in 2012.…”

Section: Potential Therapeutic Molecules In Dry Amdmentioning

confidence: 99%

Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules

Nebbioso

Lambìase

Cerini

et al. 2019

IJMS

View full text Add to dashboard Cite

The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called immunomodulatory or anti-inflammatory agents. A systematic literature search was performed to identify randomized controlled trials published prior to January 2019. Patients affected by dry AMD treated with intravitreal therapeutic agents were included. Changes in the correct visual acuity and reduction in geographic atrophy progression were evaluated. Several new drugs have shown promising results, including those targeting the complement cascade and neuroprotective agents. The potential action of the two groups of drugs is to block complement cascade upregulation of immunomodulating agents, and to prevent the degeneration and apoptosis of ganglion cells for the neuroprotectors, respectively. Our analysis indicates that finding treatments for dry AMD will require continued collaboration among researchers to identify additional molecular targets and to fully interrogate the utility of pluripotent stem cells for personalized therapy.

show abstract

Therapeutic effects of various therapeutic strategies on non-exudative age-related macular degeneration

Cited by 10 publications

References 34 publications

Age-Related Macular Degeneration Preferred Practice Pattern®

Age-Related Macular Degeneration Preferred Practice Pattern®

Global Burden of Dry Age-Related Macular Degeneration: A Targeted Literature Review

Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules

Contact Info

Product

Resources

About